Fundamental Analysis of GENEURO SA(EPA:GNRO) stock

Fundamental Rating

GNRO gets a fundamental rating of 0 out of 10. The analysis compared the fundamentals against 73 industry peers in the Biotechnology industry. GNRO has a bad profitability rating. Also its financial health evaluation is rather negative. GNRO does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

GNRO had negative earnings in the past year.

In the past year GNRO has reported a negative cash flow from operations.

In the past 5 years GNRO always reported negative net income.

GNRO had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

GNRO's Return On Assets of -231.93% is on the low side compared to the rest of the industry. GNRO is outperformed by 91.04% of its industry peers.

		Industry Rank	Sector Rank
ROA	-231.93%
ROE	N/A
ROIC	N/A

ROA(3y)-130.9%

ROA(5y)-115.72%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for GNRO so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

Compared to 1 year ago, GNRO has about the same amount of shares outstanding.

Compared to 5 years ago, GNRO has more shares outstanding

The debt/assets ratio for GNRO is higher compared to a year ago.

2.2 Solvency

Based on the Altman-Z score of -20.66, we must say that GNRO is in the distress zone and has some risk of bankruptcy.

With a Altman-Z score value of -20.66, GNRO is not doing good in the industry: 83.58% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Altman-Z	-20.66

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

A Current Ratio of 0.37 indicates that GNRO may have some problems paying its short term obligations.

GNRO has a worse Current ratio (0.37) than 92.54% of its industry peers.

GNRO has a Quick Ratio of 0.37. This is a bad value and indicates that GNRO is not financially healthy enough and could expect problems in meeting its short term obligations.

Looking at the Quick ratio, with a value of 0.37, GNRO is doing worse than 91.04% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	0.37
Quick Ratio	0.37

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

GNRO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -17.23%.

EPS 1Y (TTM)-17.23%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-22.27%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y-28.12%

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next Year-100%

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

GNRO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year GNRO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2YN/A

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for GNRO!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

GENEURO SA

EPA:GNRO (1/6/2025, 7:00:00 PM)

0.0682

-0.01 (-11.43%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)07-25 2024-07-25

Earnings (Next)N/A N/A

Inst Owners23.81%

Inst Owner ChangeN/A

Ins OwnersN/A

Ins Owner ChangeN/A

Market Cap2.03M

Analysts85.71

Price Target7.24 (10515.84%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)0%

EPS NY rev (3m)0%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	N/A
P/tB	N/A
EV/EBITDA	N/A

EPS(TTM)-0.6

EYN/A

EPS(NY)-0.42

Fwd EYN/A

FCF(TTM)-0.34

FCFYN/A

OCF(TTM)-0.34

OCFYN/A

SpS0

BVpS-0.46

TBVpS-0.5

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-231.93%
ROE	N/A
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-130.9%

ROA(5y)-115.72%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score3

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	8.51%
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	0.37
Quick Ratio	0.37
Altman-Z	-20.66

F-Score3

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)14.31%

Cap/Depr(5y)12.72%

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-17.23%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-22.27%

EPS Next Y-28.12%

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next Year-100%

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-27.82%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year-30.49%

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y22.46%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y22.31%

OCF growth 3YN/A

OCF growth 5YN/A

GENEURO SA (GNRO.PA)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens